ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
04/20/201406:17:33MARKET SNAPSHOT: Long View On Stocks Is Best During Weak Earnings...
04/11/201419:36:07Riding the Tech Roller Coaster
03/30/201408:44:49New Drugs to Lower Cholesterol Show Promise: Studies
03/26/201416:30:44Merck, Glaxo Hold Off on Help With Affordable Care Act Copays
03/17/201410:14:16Amgen Says Cholesterol Drug Study Meets Primary Endpoint
03/07/201417:42:46FDA Advises of Adverse Effects from New Cholesterol Drugs
02/05/201408:18:12Lazard Ltd. Swings to Fourth-Quarter Profit
02/05/201408:10:08Merck 4Q Profit Falls 14%; Confirms Collaborations
02/05/201407:47:05Merck Profit Falls 14% on Sales Drop; Confirms Collaborations...
01/29/201409:39:35U.S. Hot Stocks: Hot Stocks to Watch
01/28/201417:20:06Amgen Profit Rises 30% on Broad Sales Growth
01/26/201408:16:39MARKET SNAPSHOT: Stock Investors Trash Market Darlings, Face...
01/02/201403:53:22UCB, Amgen Announce Trial Success for Osteoporosis Medicine
11/15/201308:55:36Highbridge Capital Management 3Q 13F: Holdings As -2-
11/15/201308:55:35Highbridge Capital Management 3Q 13F: Holdings As Of Sep 30
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30 -2-
11/15/201308:53:17D. E. Shaw & Co. LP 3Q 13F: Holdings As Of Sep 30
11/15/201308:39:34Kingdon Capital Management 3Q 13F: Holdings As Of -2-
11/15/201308:39:34Kingdon Capital Management 3Q 13F: Largest Purchases
11/15/201308:39:33Kingdon Capital Management 3Q 13F: Holdings As Of Sep 30

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad